on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies at the Emerging Outlook: Biotech Summit conference
DBV Technologies, a late-stage biopharmaceutical company, announced that its CEO, Daniel Tassé, will participate in the Emerging Outlook: Biotech Summit, hosted by Guggenheim Securities. The event will take place in New York City on February 11 and 12, 2026. Mr. Tassé will participate in an informal discussion on February 12 at 2:30 p.m. Eastern Time.
A live webcast of this discussion is available on the company's website. A recording will also be available for 90 days. DBV Technologies, specializing in food allergy treatments, is currently focusing on its proprietary technology, the VIASKIN® patch, designed to desensitize the immune system to allergens.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news